<DOC>
	<DOCNO>NCT00150462</DOCNO>
	<brief_summary>The purpose study test safety tolerability carfilzomib different dose level hematological cancer multiple myeloma , non-Hodgkin 's lymphoma , Hodgkin 's disease , Waldenstrom 's macroglobulinemia . Carfilzomib proteasome inhibitor , enzyme responsible degrading wide variety cellular protein .</brief_summary>
	<brief_title>Safety Study Proteasome Inhibitor PR-171 ( Carfilzomib Injection ) Patients With Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1 . Written inform consent accordance federal , local , institutional guideline 2 . Males females ≥18 year age 3 . Histologically confirm diagnosis one hematologic malignancy : Multiple myeloma ( MM ) NonHodgkin 's lymphoma ( NHL ) Waldenström 's Macroglobulinemia ( WM ) Hodgkin 's disease ( HD ) 4 . Subjects refractory relapse follow least two prior therapy 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 6 . Adequate cardiovascular function without symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction previous six month 7 . Adequate hepatic function , bilirubin &lt; 2.0 time upper limit normal , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3.0 time upper limit normal 8 . Total white blood cell ( WBC ) count ≥ 2,000/mm³ , absolute neutrophil count ( ANC ) ≥ 1000/mm³ , hemoglobin ≥ 8.0 g/dL , platelet count ≥ 50,000/mm³ Screening ANC independent granulocyte colony stimulate factor ( GCSF ) granulocytemacrophage colonystimulating factor ( GMCSF ) support ≥ 1 week pegylated GCSF ≥ 2 week ) Subjects receive supportive care include erythropoietin , darbepoetin and/or bisphosphonates continue , must transfusion independent ; subject receive erythropoietic support must remain dose first 28 day study participation 9 . An estimated creatinine clearance ≥ 30 mL/min , calculate use formula Cockroft Gault 10 . Serum creatinine ≤ 2.0 mg/dL 11 . Uric acid , elevate , must correct within laboratory normal range prior dose 12 . Female subject childbearing potential must agree use dual method contraception negative serum pregnancy test . Male subject must use effective barrier method contraception throughout study three month follow last dose sexually active female childbearing potential . 1 . Female subject pregnant lactate 2 . Subjects transfusion dependent 3 . Subjects NHL HL receive steroid therapy previous seven day 4 . Subjects MM Waldenström 's Macroglobulinemia receive steroid therapy previous three week , except MM subject Carfilzomib + DEX Expansion Cohort , previous treatment dexamethasone allow . The dose schedule administration dexamethasone adjust use protocol 5 . Radiation , chemotherapy , immunotherapy previous four week , subject , judgment Investigator , recover effect previous therapy 6 . For Dose Escalation period , subject receive prior radioimmunotherapy anticluster differentiation ( CD ) 20 monoclonal antibody Bexxar® Zevalin® ; subject treat product allow Dose Expansion period 7 . Subjects receive allogeneic stem cell transplant therapy 8 . Subjects NHL HL receive autologous stem cell transplant therapy relapse within 100 day therapy 9 . Rituxan therapy within three month Day 1 unless evidence disease progression 10 . Major surgery within three week Day 1 11 . Congestive heart failure ( CHF ) ( New York Heart Association class III IV ) 12 . Acute active infection require systemic antibiotic , antiviral , antifungal within two week prior first dose 13 . Subjects know suspected human immunodeficiency virus ( HIV ) infection HIV seropositive 14 . Active hepatitis A , B , C infection ; positive Hepatitis C ribonucleic acid ( RNA ) hepatitis B antigen 15 . Nonhematologic malignancy within past three year except ) adequately treat basal cell squamous cell skin cancer , b ) carcinoma situ cervix , c ) prostate cancer stable prostate specific antigen ( PSA ) level three year 16 . Subjects treatmentrelated myelodysplastic disorder 17 . Subjects know brain metastasis ( active central nervous system [ CNS ] disease ) 18 . Serious psychiatric medical condition could interfere treatment 19 . Participation investigational therapeutic study within one month prior Day 1 20 . Significant neurotoxicity ( Grade 2 high pain ) time study initiation 21 . Concurrent therapy approve investigative anticancer therapeutic 22 . Subjects previous hypersensitivity bortezomib injection 23 . Subjects contraindication receive allopurinol 24 . Subjects require program oral intravenous fluid hydration contraindicate , e.g. , due preexist pulmonary , cardiac , renal impairment 25 . Subjects know suspected amyloidosis 26 . Subjects pleural effusion require thoracentesis ascites require paracentesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hematological</keyword>
	<keyword>Proteasome</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Lymphoma</keyword>
</DOC>